Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Identifieur interne : 00B162 ( Main/Exploration ); précédent : 00B161; suivant : 00B163Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Auteurs : Stephen G. O'Brien [Royaume-Uni, France, États-Unis, Suisse, Italie, Espagne, Pays-Bas, Allemagne, Australie, Suède] ; Francois Guilhot ; Richard A. Larson ; Insa Gathmann ; Michele Baccarani ; Francisco Cervantes ; Jan J. Cornelissen ; Thomas Fischer ; Andreas Hochhaus ; Timothy Hughes ; Klaus Lechner ; Johan L. Nielsen ; Philippe Rousselot ; Josy Reiffers ; Giuseppe Saglio ; John Shepherd ; Bengt Simonsson ; Alois Gratwohl ; John M. Goldman ; Hagop Kantarjian ; Kerry Taylor ; Gregor Verhoef ; Ann E. Bolton ; Renaud Capdeville ; Brian J. DrukerSource :
- The New England journal of medicine [ 0028-4793 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
BACKGROUND Imatinib, a selective inhibitor ofthe BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy ofimatinib with that ofinterferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML. METHODS We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover to the alternative group was allowed if stringent criteria defining treatment failure or intolerance were met. Patients were evaluated for hematologic and cytogenetic responses, toxic effects, and rates ofprogression. RESULTS After a median follow-up of 19 months, the estimated rate of a major cytogenetic response (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome) at 18 months was 87.1 percent (95 percent confidence interval, 84.1 to 90.0) in the imatinib group and 34.7 percent (95 percent confidence interval, 29.3 to 40.0) in the group given interferon alfa plus cytarabine (P<0.001). The estimated rates of complete cytogenetic response were 76.2 percent (95 percent confidence interval, 72.5 to 79.9) and 14.5 percent (95 percent confidence interval, 10.5 to 18.5), respectively (P<0.001). At 18 months, the estimated rate offreedom from progression to accelerated-phase or blast-crisis CML was 96.7 percent in the imatinib group and 91.5 percent in the combination-therapy group (P<0.001). Imatinib was better tolerated than combination therapy. CONCLUSIONS In terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML.
Affiliations:
- Allemagne, Australie, Espagne, France, Italie, Pays-Bas, Royaume-Uni, Suisse, Suède, États-Unis
- Bade-Wurtemberg, Catalogne, District de Karlsruhe, Hollande-Méridionale, Illinois, Nouvelle-Aquitaine, Poitou-Charentes, Rhénanie-Palatinat, Vienne (Autriche)
- Barcelone, Chicago, Mannheim, Mayence, Poitiers, Rotterdam, Vienne (Autriche)
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 005399
- to stream PascalFrancis, to step Curation: 000D27
- to stream PascalFrancis, to step Checkpoint: 004F42
- to stream Main, to step Merge: 00BF27
- to stream Main, to step Curation: 00B162
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia</title><author><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Newcastle</s1><s2>Newcastle</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>University of Newcastle</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Centre Hospitalier Universitaire de Poitiers</s1><s2>Poitiers</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Poitou-Charentes</region><settlement type="city">Poitiers</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Universiw of Chicago</s1><s2>Chicago</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Novartis</s1><s2>Basel</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>Novartis</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Policlinico S. Orsola-Malpighi</s1><s2>Bologna</s2><s3>ITA</s3></inist:fA14><country>Italie</country><wicri:noRegion>Policlinico S. Orsola-Malpighi</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hospital Clinic I Provincial</s1><s2>Barcelona</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Erasmus Medical Center, Daniel Den Hoed Cancer Center</s1><s2>Rotterdam</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Johannes-Gutenberg-Universität</s1><s2>Mainz</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Klinikum Mannheim, Universität Heidelberg</s1><s2>Mannheim</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Royal Adelaide Hospital</s1><s2>Adelaide</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Royal Adelaide Hospital</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Universitäts Klinik für Innere Medizin I</s1><s2>Vienna</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Aarhus Amtssygehus</s1><s2>Aarhus</s2><s3>FRA</s3></inist:fA14><country>France</country><wicri:noRegion>Aarhus</wicri:noRegion><wicri:noRegion>Aarhus Amtssygehus</wicri:noRegion><wicri:noRegion>Aarhus Amtssygehus</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Azienda Ospedaliera S. Luigi</s1><s2>Gonzaga, Orbassano</s2><s3>ITA</s3></inist:fA14><country>Italie</country><wicri:noRegion>Azienda Ospedaliera S. Luigi</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Akademiska Sjukhuset</s1><s2>Uppsala</s2><s3>SWE</s3></inist:fA14><country>Suède</country><wicri:noRegion>Akademiska Sjukhuset</wicri:noRegion></affiliation></author><author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="Francois" last="Guilhot">Francois Guilhot</name></author><author><name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A." last="Larson">Richard A. Larson</name></author><author><name sortKey="Gathmann, Insa" sort="Gathmann, Insa" uniqKey="Gathmann I" first="Insa" last="Gathmann">Insa Gathmann</name></author><author><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></author><author><name sortKey="Cervantes, Francisco" sort="Cervantes, Francisco" uniqKey="Cervantes F" first="Francisco" last="Cervantes">Francisco Cervantes</name></author><author><name sortKey="Cornelissen, Jan J" sort="Cornelissen, Jan J" uniqKey="Cornelissen J" first="Jan J." last="Cornelissen">Jan J. Cornelissen</name></author><author><name sortKey="Fischer, Thomas" sort="Fischer, Thomas" uniqKey="Fischer T" first="Thomas" last="Fischer">Thomas Fischer</name></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name></author><author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name></author><author><name sortKey="Lechner, Klaus" sort="Lechner, Klaus" uniqKey="Lechner K" first="Klaus" last="Lechner">Klaus Lechner</name></author><author><name sortKey="Nielsen, Johan L" sort="Nielsen, Johan L" uniqKey="Nielsen J" first="Johan L." last="Nielsen">Johan L. Nielsen</name></author><author><name sortKey="Rousselot, Philippe" sort="Rousselot, Philippe" uniqKey="Rousselot P" first="Philippe" last="Rousselot">Philippe Rousselot</name></author><author><name sortKey="Reiffers, Josy" sort="Reiffers, Josy" uniqKey="Reiffers J" first="Josy" last="Reiffers">Josy Reiffers</name></author><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name></author><author><name sortKey="Shepherd, John" sort="Shepherd, John" uniqKey="Shepherd J" first="John" last="Shepherd">John Shepherd</name></author><author><name sortKey="Simonsson, Bengt" sort="Simonsson, Bengt" uniqKey="Simonsson B" first="Bengt" last="Simonsson">Bengt Simonsson</name></author><author><name sortKey="Gratwohl, Alois" sort="Gratwohl, Alois" uniqKey="Gratwohl A" first="Alois" last="Gratwohl">Alois Gratwohl</name></author><author><name sortKey="Goldman, John M" sort="Goldman, John M" uniqKey="Goldman J" first="John M." last="Goldman">John M. Goldman</name></author><author><name sortKey="Kantarjian, Hagop" sort="Kantarjian, Hagop" uniqKey="Kantarjian H" first="Hagop" last="Kantarjian">Hagop Kantarjian</name></author><author><name sortKey="Taylor, Kerry" sort="Taylor, Kerry" uniqKey="Taylor K" first="Kerry" last="Taylor">Kerry Taylor</name></author><author><name sortKey="Verhoef, Gregor" sort="Verhoef, Gregor" uniqKey="Verhoef G" first="Gregor" last="Verhoef">Gregor Verhoef</name></author><author><name sortKey="Bolton, Ann E" sort="Bolton, Ann E" uniqKey="Bolton A" first="Ann E." last="Bolton">Ann E. Bolton</name></author><author><name sortKey="Capdeville, Renaud" sort="Capdeville, Renaud" uniqKey="Capdeville R" first="Renaud" last="Capdeville">Renaud Capdeville</name></author><author><name sortKey="Druker, Brian J" sort="Druker, Brian J" uniqKey="Druker B" first="Brian J." last="Druker">Brian J. Druker</name></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">03-0195409</idno><date when="2003">2003</date><idno type="stanalyst">PASCAL 03-0195409 INIST</idno><idno type="RBID">Pascal:03-0195409</idno><idno type="wicri:Area/PascalFrancis/Corpus">005399</idno><idno type="wicri:Area/PascalFrancis/Curation">000D27</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">004F42</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004F42</idno><idno type="wicri:doubleKey">0028-4793:2003:O Brien S:imatinib:compared:with</idno><idno type="wicri:Area/Main/Merge">00BF27</idno><idno type="wicri:Area/Main/Curation">00B162</idno><idno type="wicri:Area/Main/Exploration">00B162</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia</title><author><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>University of Newcastle</s1><s2>Newcastle</s2><s3>GBR</s3></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>University of Newcastle</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Centre Hospitalier Universitaire de Poitiers</s1><s2>Poitiers</s2><s3>FRA</s3></inist:fA14><country>France</country><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Poitou-Charentes</region><settlement type="city">Poitiers</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Universiw of Chicago</s1><s2>Chicago</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Chicago</settlement><region type="state">Illinois</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Novartis</s1><s2>Basel</s2><s3>CHE</s3></inist:fA14><country>Suisse</country><wicri:noRegion>Novartis</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Policlinico S. Orsola-Malpighi</s1><s2>Bologna</s2><s3>ITA</s3></inist:fA14><country>Italie</country><wicri:noRegion>Policlinico S. Orsola-Malpighi</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="06"><s1>Hospital Clinic I Provincial</s1><s2>Barcelona</s2><s3>ESP</s3></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Erasmus Medical Center, Daniel Den Hoed Cancer Center</s1><s2>Rotterdam</s2><s3>NLD</s3></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Rotterdam</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Johannes-Gutenberg-Universität</s1><s2>Mainz</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="2">Rhénanie-Palatinat</region><settlement type="city">Mayence</settlement></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Klinikum Mannheim, Universität Heidelberg</s1><s2>Mannheim</s2><s3>DEU</s3></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Mannheim</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Royal Adelaide Hospital</s1><s2>Adelaide</s2><s3>AUS</s3></inist:fA14><country>Australie</country><wicri:noRegion>Royal Adelaide Hospital</wicri:noRegion></affiliation><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Universitäts Klinik für Innere Medizin I</s1><s2>Vienna</s2><s3>USA</s3></inist:fA14><country>États-Unis</country><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Aarhus Amtssygehus</s1><s2>Aarhus</s2><s3>FRA</s3></inist:fA14><country>France</country><wicri:noRegion>Aarhus</wicri:noRegion><wicri:noRegion>Aarhus Amtssygehus</wicri:noRegion><wicri:noRegion>Aarhus Amtssygehus</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>Azienda Ospedaliera S. Luigi</s1><s2>Gonzaga, Orbassano</s2><s3>ITA</s3></inist:fA14><country>Italie</country><wicri:noRegion>Azienda Ospedaliera S. Luigi</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Akademiska Sjukhuset</s1><s2>Uppsala</s2><s3>SWE</s3></inist:fA14><country>Suède</country><wicri:noRegion>Akademiska Sjukhuset</wicri:noRegion></affiliation></author><author><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="Francois" last="Guilhot">Francois Guilhot</name></author><author><name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A." last="Larson">Richard A. Larson</name></author><author><name sortKey="Gathmann, Insa" sort="Gathmann, Insa" uniqKey="Gathmann I" first="Insa" last="Gathmann">Insa Gathmann</name></author><author><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name></author><author><name sortKey="Cervantes, Francisco" sort="Cervantes, Francisco" uniqKey="Cervantes F" first="Francisco" last="Cervantes">Francisco Cervantes</name></author><author><name sortKey="Cornelissen, Jan J" sort="Cornelissen, Jan J" uniqKey="Cornelissen J" first="Jan J." last="Cornelissen">Jan J. Cornelissen</name></author><author><name sortKey="Fischer, Thomas" sort="Fischer, Thomas" uniqKey="Fischer T" first="Thomas" last="Fischer">Thomas Fischer</name></author><author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name></author><author><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name></author><author><name sortKey="Lechner, Klaus" sort="Lechner, Klaus" uniqKey="Lechner K" first="Klaus" last="Lechner">Klaus Lechner</name></author><author><name sortKey="Nielsen, Johan L" sort="Nielsen, Johan L" uniqKey="Nielsen J" first="Johan L." last="Nielsen">Johan L. Nielsen</name></author><author><name sortKey="Rousselot, Philippe" sort="Rousselot, Philippe" uniqKey="Rousselot P" first="Philippe" last="Rousselot">Philippe Rousselot</name></author><author><name sortKey="Reiffers, Josy" sort="Reiffers, Josy" uniqKey="Reiffers J" first="Josy" last="Reiffers">Josy Reiffers</name></author><author><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name></author><author><name sortKey="Shepherd, John" sort="Shepherd, John" uniqKey="Shepherd J" first="John" last="Shepherd">John Shepherd</name></author><author><name sortKey="Simonsson, Bengt" sort="Simonsson, Bengt" uniqKey="Simonsson B" first="Bengt" last="Simonsson">Bengt Simonsson</name></author><author><name sortKey="Gratwohl, Alois" sort="Gratwohl, Alois" uniqKey="Gratwohl A" first="Alois" last="Gratwohl">Alois Gratwohl</name></author><author><name sortKey="Goldman, John M" sort="Goldman, John M" uniqKey="Goldman J" first="John M." last="Goldman">John M. Goldman</name></author><author><name sortKey="Kantarjian, Hagop" sort="Kantarjian, Hagop" uniqKey="Kantarjian H" first="Hagop" last="Kantarjian">Hagop Kantarjian</name></author><author><name sortKey="Taylor, Kerry" sort="Taylor, Kerry" uniqKey="Taylor K" first="Kerry" last="Taylor">Kerry Taylor</name></author><author><name sortKey="Verhoef, Gregor" sort="Verhoef, Gregor" uniqKey="Verhoef G" first="Gregor" last="Verhoef">Gregor Verhoef</name></author><author><name sortKey="Bolton, Ann E" sort="Bolton, Ann E" uniqKey="Bolton A" first="Ann E." last="Bolton">Ann E. Bolton</name></author><author><name sortKey="Capdeville, Renaud" sort="Capdeville, Renaud" uniqKey="Capdeville R" first="Renaud" last="Capdeville">Renaud Capdeville</name></author><author><name sortKey="Druker, Brian J" sort="Druker, Brian J" uniqKey="Druker B" first="Brian J." last="Druker">Brian J. Druker</name></author></analytic><series><title level="j" type="main">The New England journal of medicine</title><title level="j" type="abbreviated">N. Engl. j. med.</title><idno type="ISSN">0028-4793</idno><imprint><date when="2003">2003</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">The New England journal of medicine</title><title level="j" type="abbreviated">N. Engl. j. med.</title><idno type="ISSN">0028-4793</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term><term>Chronic</term><term>Chronic myelocytic leukemia</term><term>Cytarabine</term><term>Diagnosis</term><term>Drug combination</term><term>Human</term><term>Interferon</term><term>Low dose</term><term>Multicenter study</term><term>Phase III trial</term><term>Pyrimidine nucleoside</term><term>Secondary effect</term><term>Tolerance</term><term>Treatment efficiency</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Leucémie myéloïde</term><term>Diagnostic</term><term>Chimiothérapie</term><term>Interféron</term><term>Association médicamenteuse</term><term>Dose faible</term><term>Cytarabine</term><term>Effet secondaire</term><term>Tolérance</term><term>Etude multicentrique</term><term>Essai clinique phase III</term><term>Efficacité traitement</term><term>Homme</term><term>Chronique</term><term>Pyrimidine nucléoside</term><term>Imatinib</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">BACKGROUND Imatinib, a selective inhibitor ofthe BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa. We compared the efficacy ofimatinib with that ofinterferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML. METHODS We randomly assigned 1106 patients to receive imatinib (553 patients) or interferon alfa plus low-dose cytarabine (553 patients). Crossover to the alternative group was allowed if stringent criteria defining treatment failure or intolerance were met. Patients were evaluated for hematologic and cytogenetic responses, toxic effects, and rates ofprogression. RESULTS After a median follow-up of 19 months, the estimated rate of a major cytogenetic response (0 to 35 percent of cells in metaphase positive for the Philadelphia chromosome) at 18 months was 87.1 percent (95 percent confidence interval, 84.1 to 90.0) in the imatinib group and 34.7 percent (95 percent confidence interval, 29.3 to 40.0) in the group given interferon alfa plus cytarabine (P<0.001). The estimated rates of complete cytogenetic response were 76.2 percent (95 percent confidence interval, 72.5 to 79.9) and 14.5 percent (95 percent confidence interval, 10.5 to 18.5), respectively (P<0.001). At 18 months, the estimated rate offreedom from progression to accelerated-phase or blast-crisis CML was 96.7 percent in the imatinib group and 91.5 percent in the combination-therapy group (P<0.001). Imatinib was better tolerated than combination therapy. CONCLUSIONS In terms of hematologic and cytogenetic responses, tolerability, and the likelihood of progression to accelerated-phase or blast-crisis CML, imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li><li>Suisse</li><li>Suède</li><li>États-Unis</li></country><region><li>Bade-Wurtemberg</li><li>Catalogne</li><li>District de Karlsruhe</li><li>Hollande-Méridionale</li><li>Illinois</li><li>Nouvelle-Aquitaine</li><li>Poitou-Charentes</li><li>Rhénanie-Palatinat</li><li>Vienne (Autriche)</li></region><settlement><li>Barcelone</li><li>Chicago</li><li>Mannheim</li><li>Mayence</li><li>Poitiers</li><li>Rotterdam</li><li>Vienne (Autriche)</li></settlement></list><tree><noCountry><name sortKey="Baccarani, Michele" sort="Baccarani, Michele" uniqKey="Baccarani M" first="Michele" last="Baccarani">Michele Baccarani</name><name sortKey="Bolton, Ann E" sort="Bolton, Ann E" uniqKey="Bolton A" first="Ann E." last="Bolton">Ann E. Bolton</name><name sortKey="Capdeville, Renaud" sort="Capdeville, Renaud" uniqKey="Capdeville R" first="Renaud" last="Capdeville">Renaud Capdeville</name><name sortKey="Cervantes, Francisco" sort="Cervantes, Francisco" uniqKey="Cervantes F" first="Francisco" last="Cervantes">Francisco Cervantes</name><name sortKey="Cornelissen, Jan J" sort="Cornelissen, Jan J" uniqKey="Cornelissen J" first="Jan J." last="Cornelissen">Jan J. Cornelissen</name><name sortKey="Druker, Brian J" sort="Druker, Brian J" uniqKey="Druker B" first="Brian J." last="Druker">Brian J. Druker</name><name sortKey="Fischer, Thomas" sort="Fischer, Thomas" uniqKey="Fischer T" first="Thomas" last="Fischer">Thomas Fischer</name><name sortKey="Gathmann, Insa" sort="Gathmann, Insa" uniqKey="Gathmann I" first="Insa" last="Gathmann">Insa Gathmann</name><name sortKey="Goldman, John M" sort="Goldman, John M" uniqKey="Goldman J" first="John M." last="Goldman">John M. Goldman</name><name sortKey="Gratwohl, Alois" sort="Gratwohl, Alois" uniqKey="Gratwohl A" first="Alois" last="Gratwohl">Alois Gratwohl</name><name sortKey="Guilhot, Francois" sort="Guilhot, Francois" uniqKey="Guilhot F" first="Francois" last="Guilhot">Francois Guilhot</name><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name><name sortKey="Hughes, Timothy" sort="Hughes, Timothy" uniqKey="Hughes T" first="Timothy" last="Hughes">Timothy Hughes</name><name sortKey="Kantarjian, Hagop" sort="Kantarjian, Hagop" uniqKey="Kantarjian H" first="Hagop" last="Kantarjian">Hagop Kantarjian</name><name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A." last="Larson">Richard A. Larson</name><name sortKey="Lechner, Klaus" sort="Lechner, Klaus" uniqKey="Lechner K" first="Klaus" last="Lechner">Klaus Lechner</name><name sortKey="Nielsen, Johan L" sort="Nielsen, Johan L" uniqKey="Nielsen J" first="Johan L." last="Nielsen">Johan L. Nielsen</name><name sortKey="Reiffers, Josy" sort="Reiffers, Josy" uniqKey="Reiffers J" first="Josy" last="Reiffers">Josy Reiffers</name><name sortKey="Rousselot, Philippe" sort="Rousselot, Philippe" uniqKey="Rousselot P" first="Philippe" last="Rousselot">Philippe Rousselot</name><name sortKey="Saglio, Giuseppe" sort="Saglio, Giuseppe" uniqKey="Saglio G" first="Giuseppe" last="Saglio">Giuseppe Saglio</name><name sortKey="Shepherd, John" sort="Shepherd, John" uniqKey="Shepherd J" first="John" last="Shepherd">John Shepherd</name><name sortKey="Simonsson, Bengt" sort="Simonsson, Bengt" uniqKey="Simonsson B" first="Bengt" last="Simonsson">Bengt Simonsson</name><name sortKey="Taylor, Kerry" sort="Taylor, Kerry" uniqKey="Taylor K" first="Kerry" last="Taylor">Kerry Taylor</name><name sortKey="Verhoef, Gregor" sort="Verhoef, Gregor" uniqKey="Verhoef G" first="Gregor" last="Verhoef">Gregor Verhoef</name></noCountry><country name="Royaume-Uni"><noRegion><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></noRegion></country><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></region><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></country><country name="États-Unis"><region name="Illinois"><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></region><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></country><country name="Suisse"><noRegion><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></noRegion></country><country name="Italie"><noRegion><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></noRegion><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></country><country name="Espagne"><region name="Catalogne"><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></region></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></region></country><country name="Allemagne"><region name="Rhénanie-Palatinat"><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></region><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></country><country name="Australie"><noRegion><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></noRegion></country><country name="Suède"><noRegion><name sortKey="O Brien, Stephen G" sort="O Brien, Stephen G" uniqKey="O Brien S" first="Stephen G." last="O'Brien">Stephen G. O'Brien</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00B162 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00B162 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:03-0195409
|texte= Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
}}
| This area was generated with Dilib version V0.6.33. |  |